Combining ublituximab with the novel PI3K inhibitor TGR-1202 for CLL
Potential second-line treatment for indolent lymphoma
CAR T-cells and fast cars
The exciting field of imaging in multiple myeloma
Jens Hillengass et al.
Overview of novel restore and target treatment approach to classical Hodgkin lymphoma